Acquisition - November 7, 2014
MedImmune Acquires Definiens
MedImmune, AstraZeneca’s global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has developed an imaging and data analysis technology known as Tissue Phenomics™. The new technology significantly improves the identification of biomarkers in tumor tissue. According to the agreement, MedImmune will acquire 100 percent of Definiens’ […]
Uncategorized - November 7, 2014
Vaccine Reduces Tumor Growth
Researchers from Uppsala University in Sweden have shown that a therapeutic vaccine aimed at tumor blood vessels suppresses tumor growth and metastasis. The work focused on lung metastases in a mouse model for metastatic breast cancer. “The vaccination approach we have employed is not prophylactic but therapeutic, meaning that immunity was induced after the onset […]
Biotech article - November 6, 2014
Norway Joins Biotech Assoc.
The Norwegian Bioindustry Association is one of 20 founding members of the International Council of Biotechnology Associations (ICBA). The goal of the ICBA is to advocate for public policies that support the growth of the biotechnology industry worldwide. Jim Greenwood, president and chief executive officer of the Biotechnology Industry Organization in the U.S., was elected […]
In a new job - November 5, 2014
Targovax Names New CEO
Gunnar Gårdemyr has been named the new CEO of Norwegian company Targovax, effective Jan. 12, 2015. Gårdemyr has spent 30 years in the international pharmaceutical and biotech industries and brings experience in management, business development, mergers and acquisitions, global marketing and commercial strategy to Targovax. Currently he is the corporate advisor for Acino Pharma in […]
Pharma article - November 5, 2014
AZ’s Healthy Heart Africa
AstraZeneca’s new Healthy Heart Africa program is aimed at increasing awareness of the symptoms and risks of hypertension among vulnerable populations in Africa. Initially launching in Kenya, the program will provide education, screening, treatment and methods to control hypertension. AstraZeneca is collaborating with non-government organizations from Kenya and other countries to offer support to local […]
Clinical Trials - November 5, 2014
PMDD Drug Shows Promise
A candidate drug developed by Umecrine Mood AB to treat premenstrual dysphoric disorder (PMDD) showed positive results during a randomized Phase I/II study. Those taking the drug called UC1010 showed a significant reduction in PMDD symptoms compared to those taking a placebo. “UC1010 has been developed specifically to target the atypical effects of progesterone metabolites […]
